Mohammad Akbarpour

Mohammad Akbarpour

Auto-generated profile, based on publicly available information

Mohammad Akbarpour

Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Journal of Kerman University of Medical Sciences
Verified
Journal Article
Open access
PDF file
SVShahrzad Sadat Eftekhar Vaghefi
Shahrzad Sadat Eftekhar Vaghefi
MAMohammad Akbarpour
Mohammad Akbarpour
FSFatemeh Shahsavari
Fatemeh Shahsavari
MKMohammad Ehsan Khani
Mohammad Ehsan Khani
AGAmir Mahdi Kouhsefidi Gouderi
Amir Mahdi Kouhsefidi Gouderi
RAReza Malekpour Afshar
Reza Malekpour Afshar
Background: Antibiotic resistance is a worldwide concern that decreases the beneficial effects of antibiotics. Escherichia coli is a prevalent etiological agent of infections, particularly within hospital intensive care units. Therefore, comprehending the antibiotic resistance profile of E. coli is essential for effective treatment. This study evaluated the antibiotic resistance characteristics of E. coli collected from patients admitted to Afzalipour hospital in Kerman, Iran. Methods: This retrospective study examined 139 patients hospitalized at Afzalipour hospital between September 2017 and August 2019. E. coli isolates from clinical specimens were evaluated for antibiotic susceptibility using disk diffusion and agar dilution techniques. The data were analyzed with a chi-square test in SPSS. Results: Cefazolin and cefotaxime were the most resistant drugs within the examined population. In contrast, gentamicin and amikacin demonstrated reduced resistance rates. The resistance level varied based on the sample type and the department where the patients were admitted. Conclusion: Excessive and wrong uses of antibiotics develop antibiotic resistance in E. coli. Therefore, gentamicin and amikacin can be considered to reduce antibiotic resistance challenges.